 |
Public
Meeting for Levothyroxine Sodium Therapeutic Equivalence
May 23, 2005, Washington, DC
The Food and Drug Administration (FDA) is announcing a public
meeting on the therapeutic equivalence of levothyroxine sodium drug
products. This meeting is being held in co-sponsorship with three
medical societies: The American Thyroid Association (ATA), the
Endocrine Society, and the American Association of Clinical
Endocrinologists (AACE). The purpose of the public meeting is to discuss FDA's
regulatory standards and methodological approaches for determining
therapeutic equivalence between levothyroxine sodium drug products.
| Extension of comment
period. FDA is extending until September 23, 2005
the time to submit written or electronic comments in response
to the May 23, 2005 public meeting on the therapeutic
equivalence of levothyroxine sodium drug products. (7/22/2005) |
 PDF requires the free Adobe
Acrobat Reader
 Back
to Top 
Back to Workshops
Date created: April 22, 2005, updated July 22,
2005 |
|
